



133 Molesworth Street
PO Box 5013
Wellington 6140
New Zealand
T+64 4 496 2000

29 June 2022

s 9(2)(a)

By email: s 9(2)(a)

Ref: H202207305

Tēnā koe s 9(2)(a)

Response to your request for official information

Thank you for your request under the Official Information Act 1982 (the Act) to the Ministry of Health (the Ministry) on 30 May 2022 for information relating to Budget 2022. Please find a response to each part of your request below:

'How much of the funding is allocated to the post-diagnostic dementia trials vs the support for family members delivering respite care?'

\$7.6 million has been allocated over four years for four post-diagnostic trials and Dementia Navigators to coordinate the post-diagnostic support and work with people with dementia mate wareware and their whānau and carers. Post-diagnostic sessions will include information and support for carers.

\$4.4 million has been allocated over four years for innovative respite care to trial options for flexible and person-centred respite for carers of people with dementia.

'Who can access / what is the criteria for accessing the post-diagnostic support funding? E.g. can residential/aged cared organisations (e.g. Oceania Healthcare) access the funding?'

Post-diagnostic support is to be provided to people newly diagnosed with dementia.

All initiatives within the scope of this funding are expected to be community based and will include a focus on addressing the needs of one of more of the priority groups – Māori, Pacific, rural populations and people with earlier onset dementia mate wareware.

The process for establishing the trials, and applications for trial sites, will be developed alongside the Dementia Mate Wareware Leadership Group.

'When will it be available?'

Implementation of the initiative will begin in 2022/23, with specific timeframes being worked through. There is significant development work that will need to occur prior to the trials being established, such as the development of the Dementia Navigator role and a programme of support for newly diagnosed people.

'What is the process to apply for the funding / the post-diagnostic support trials?'

This is being worked through by Health New Zealand and will be informed by advice provided by Dementia Mate Wareware Leadership Group. Information will be made available to the sector when the process has been decided. Health New Zealand has added ANACTA Consulting to the mailout list for allocating funding.

'Do you have the contact details for a Ministry of Health official that can be contacted for further information?'

For further information for dementia related work in Health New Zealand, you may contact the interim contact, Mark Powell (Acting Group Manager, Community Health System Improvement and Innovation Commissioning) by email Mark.Powell@health.govt.nz

'Any further information on the funding/trials would be greatly appreciated.'

The health sector will be advised as further information becomes available and then announced to the public.

I trust this information fulfils your request.

Under section 28(3) of the Act, you have the right to ask the Ombudsman to review any decisions made under this request. The Ombudsman may be contacted by email at: info@ombudsman.parliament.nz or by calling 0800 802 602.

Nāku noa, nā

A handwritten signature in black ink, appearing to be 'Mark Powell', written in a cursive style.

Mark Powell
**Group Manager, Community and Rural
Health System Improvement and Innovation Primary**